These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 14519673)

  • 1. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
    Paterson PJ; Seaton S; Prentice HG; Kibbler CC
    J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.
    Martín-Mazuelos E; Pemán J; Valverde A; Chaves M; Serrano MC; Cantón E
    J Antimicrob Chemother; 2003 Sep; 52(3):365-70. PubMed ID: 12917236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD; Kiraz N
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
    Warn PA; Morrissey G; Morrissey J; Denning DW
    J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma.
    Chen J; Li H; Li R; Bu D; Wan Z
    J Antimicrob Chemother; 2005 Jan; 55(1):31-7. PubMed ID: 15563516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J; Peláez T; Alcalá L; Bouza E
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.
    Dannaoui E; Meletiadis J; Tortorano AM; Symoens F; Nolard N; Viviani MA; Piens MA; Lebeau B; Verweij PE; Grillot R; And The Ebga Network
    J Med Microbiol; 2004 Feb; 53(Pt 2):129-134. PubMed ID: 14729934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
    Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
    Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
    Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
    Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J; Peláez T; Alcalá L; Bouza E
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.
    Te Dorsthorst DT; Mouton JW; van den Beukel CJ; van der Lee HA; Meis JF; Verweij PE
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3147-50. PubMed ID: 15273136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid method for testing the susceptibility of Aspergillus fumigatus to amphotericin B, itraconazole, voriconazole and posaconazole by assessment of oxygen consumption.
    Araujo R; Coutinho I; Espinel-Ingroff A
    J Antimicrob Chemother; 2008 Dec; 62(6):1277-80. PubMed ID: 18824456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
    Manavathu EK; Cutright JL; Chandrasekar PH
    Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus.
    Dannaoui E; Borel E; Persat F; Monier MF; Piens MA; Network E
    J Med Microbiol; 1999 Dec; 48(12):1087-1093. PubMed ID: 10591162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis.
    Barchiesi F; Spreghini E; Sanguinetti M; Giannini D; Manso E; Castelli P; Girmenia C
    J Antimicrob Chemother; 2013 Nov; 68(11):2587-91. PubMed ID: 23794598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus.
    Krishnan-Natesan S; Chandrasekar PH; Alangaden GJ; Manavathu EK
    Int J Antimicrob Agents; 2008 Dec; 32(6):519-24. PubMed ID: 18775650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antifungal susceptibilities of Aspergillus spp. strains isolated from invasive aspergillosis cases].
    Gürcan S; Tikveşli M; Eryildiz C; Evci C; Ener B
    Mikrobiyol Bul; 2010 Apr; 44(2):273-8. PubMed ID: 20549962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.
    Schwartz S; Ruhnke M; Ribaud P; Reed E; Troke P; Thiel E
    Mycoses; 2007 May; 50(3):196-200. PubMed ID: 17472616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.